Medulloblastoma with myogenic and/or melanotic differentiation does not align immunohistochemically with the genetically defined molecular subgroups.

[1]  Yi-Wei Chen,et al.  Large cell/anaplastic medulloblastoma is associated with poor prognosis—a retrospective analysis at a single institute , 2017, Child's Nervous System.

[2]  Christine Haberler,et al.  Update on the integrated histopathological and genetic classification of medulloblastoma – a practical diagnostic guideline , 2016, Clinical neuropathology.

[3]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[4]  C. Sarkar,et al.  Integrating Molecular Subclassification of Medulloblastomas into Routine Clinical Practice: A Simplified Approach , 2016, Brain pathology.

[5]  C. Sarkar,et al.  WNT‐activated medulloblastoma with melanotic and myogenic differentiation: Report of a rare case , 2016, Neuropathology : official journal of the Japanese Society of Neuropathology.

[6]  S. Weis,et al.  Medulloblastoma with multi-lineage differentiation including myogenic and melanotic elements: a case report with molecular data. , 2014, Clinical neuropathology.

[7]  Jamie L. Coleman,et al.  Isochromosome 17q, MYC amplification and large cell/anaplastic phenotype in a case of medullomyoblastoma with extracranial metastases , 2012, Pediatric blood & cancer.

[8]  Scott L. Pomeroy,et al.  Molecular subgroups of medulloblastoma: the current consensus , 2011, Acta Neuropathologica.

[9]  P. Burger,et al.  Medulloblastoma with myogenic differentiation: long-term survival in a patient treated with aggressive combination therapy and autologous stem cell transplantation , 2011, Journal of Neuro-Oncology.

[10]  Arie Perry,et al.  Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups , 2011, Acta Neuropathologica.

[11]  D. Ellison,et al.  Idiosyncratic differentiation in medulloblastoma – a report of two exceptional cases , 2008, Neuropathology and applied neurobiology.

[12]  M. Vankalakunti,et al.  The role of immunohistochemistry in medullomyoblastoma – a case series highlighting divergent differentiation , 2008, Diagnostic pathology.

[13]  A. Perry,et al.  Large cell medulloblastoma with myogenic and melanotic differentiation: a case report with molecular analysis , 2008, Journal of Neuro-Oncology.

[14]  T. Merchant,et al.  Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. , 2006, The Lancet. Oncology.

[15]  S. Nema,et al.  A 3½-Year-Old Child With a Posterior Fossa Mass , 2006 .

[16]  M. Sharma,et al.  Unusually long survival in a case of medullomyoblastoma , 2005, Journal of Clinical Neuroscience.

[17]  C. Fuller,et al.  Medullomyoblastoma: A radiographic and clinicopathologic analysis of six cases and review of the literature , 2004, Cancer.

[18]  A. Perry,et al.  Large cell/anaplastic medulloblastomas and medullomyoblastomas: clinicopathological and genetic features. , 2001, Journal of neurosurgery.

[19]  T. Pietsch,et al.  Medullomyoblastoma: a histological, immunohistochemical, ultrastructural and molecular genetic study , 1998, Acta Neuropathologica.

[20]  A. Borcek,et al.  Myogenic and melanotic differentiated medulloblastoma: case report. , 2011, Turkish neurosurgery.